目的 优选薄膜-超声法制备双烟酸姜黄素酯固体脂质纳米粒的辅料配比。方法 采用HPLC测定双烟酸姜黄素酯的含量,以双烟酸姜黄素酯固体脂质纳米粒的包封率为评价指标,通过三因素三水平Box-Bebnken响应面设计试验法筛选纳米粒辅料中硬脂酸、卵磷脂的用量及聚山梨酯-80的浓度,并确定最优处方辅料配比。结果 最佳处方辅料配比为硬脂酸80 mg,卵磷脂150 mg,聚山梨酯-80(0.6%)20 mL,所得烟酸姜黄素固体脂质纳米粒包封率达65%,平均粒径为190 nm。结论 用星点设计试验优化后制剂处方的双烟酸姜黄素酯固体脂质纳米粒最优处方辅料配比适合于制备双烟酸姜黄素酯固体脂质纳米粒。
Abstract
OBJECTIVE To optimize the film-ultrasonic technique for preparing nicotinate-curcumin nanoparticles.METHODS An HPLC method was established for determination of nicotinate-curcumin. Using the entrapment efficiency of nicotinate-curcumin as the evaluation indicator, the optimum excipient formula was selected through the Box-Bebnken reponse surface design of three factors (amounts of nicotinate-curcumin and lecithin and concentration of tween-80) at three levels. RESULTS With the established optimal formula, ie 80 mg stearic acid,150 mg lecithin and 20 mL tween-80 (0.6％), the entrapment efficiency of nicotinate-curcumin approached 65％. The mean particle size was 190 nm. CONCLUSION The nicotinate-curcumin nanoparticles prepared by the film ultrasonic technique optimized by central composite design test have high entrapment efficiency, indicating that the technique is feasible.
关键词
双烟酸姜黄素酯 /
固体脂质纳米粒 /
薄膜-超声法 /
包封率
{{custom_keyword}} /
Key words
nicotinate-curcumin nanoparticle /
solid lipid nanoparticle /
film ultrasonic method /
entrapment efficiency
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LIAO D F, LI Y M, YANG W, et al. SREBP-Caveolin-1 signaling pathway mediated by nicotinic acid curcuminester anti atherosclerosis [J]. Chin J Arterioscl(中国动脉硬化杂志), 2014,22(12):1189-1193.
[2] MA Y, JING X H, YANG A D, et al. Preparation of curcumin solid lipid nanoparticles by film-ultrasonic method[J]. Chin Tradit Pat Med (中成药),2008,7:981-983.
[3] CHEN Y W, ZHANG L. Advances in nano-drug delivery systems for curcumine [J]. Med Recap (医学综述),2014,20(2).
[4] PING Q N. Nanotechnology research [N]. China Pharm News(中国医药报),2002-09-03.
[5] ZHU Z X, QIAN Y, CAO Q R, et al. Preparation and pharmacodynamic evaluation of curcumine-PLGA nanoparticles[J]. Chin Tradit Pat Med(中成药),2011,33(5):776-779.
[6] CHEN J, DAI W T, HE Z M, et al. Methodology for determination of contents and entrapment efficiency of curcumin nanostructured lipid carier[J]. Chin Remid Clin(中国药物与临床),2012,12:1550-1553.
[7] LI M T, JI H Y, TANG J L, et al. Determination of curcumin suspensions by HPLC [J]. China Pharm(中国药师),2013, (11):1648-1650.
[8] YAN X J, CHEN G Y, ZHONG M, et al. Determination of encapsulation efficiency of paeonol in eczema nanomulsion [J]. J Hunan Univ Tradit Chin Med(湖南中医药大学学报),2015,35(8):35-37,62.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金资助项目(81173047);湖南省自然科学基金资助项目(12JJ5068)
{{custom_fund}}
PDF(1624 KB)
